Before ClassPass settled on the business model it employs today, the service went through many different phases.
Founder Payal Kadakia revealed to Cheddar how she had to change up her strategy a handful of times before finally finding success.
“The third iteration was the subscription, and that’s really when it took off...and became ClassPass,” Kadakia told Cheddar.
The self-proclaimed “mission-obsessed” founder reflected on how the service started as a search engine for fitness classes, but one that didn’t offer a value proposition for users. From there, she tested out a discovery model where users could try different classes around New York City. But she says learned a lot from each of these versions.
“Always question what you’re doing and keep iterating and pivoting until you get to that North Star,” Kadakia said.
ClassPass launched in 2011. The service includes access to around 8,500 studios and is available to consumers in 49 cities.
For full interview, [click here](https://cheddar.com/videos/the-inspiration-behind-classpass).
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
